Post date: 2024-02-08 21:56:13 GMT
This chart shows distribution of institutional flows for AVIR: % institutional buyers in green and % institutional sellers in red. The proportions of the institutional flows are estimated as a % of the total volume traded in AVIR at 1600 on 02/08/2024. As the chart shows, there is more mass on the sellers side of institutional flows than on the buyers side. However, the history of institutional flows and their relative proportion over time also matters.
Atea Pharmaceuticals, Inc. (AVIR) is a clinical-stage biopharmaceutical company that specializes in developing therapies for viral infections. Founded in 2014, Atea utilizes its proprietary drug discovery platform to identify and develop novel antiviral treatments. The company's lead drug candidate, AT-527, is currently in Phase 3 clinical trials for the treatment of hepatitis C virus (HCV) infection and in Phase 2 clinical trials for the treatment of COVID-19. Atea's mission is to address unmet medical needs and provide safe and effective therapies for patients with viral infections. With a team of experienced scientists and a strong pipeline of potential treatments, Atea is well-positioned to make a significant impact in the field of antiviral therapeutics.